Piaoyang Sun, graduated from China Pharmaceutical University at 1982, andobtained doctorate on organic chemistry at 2003, now as chairman of Jiangsu HengruiMedicine Co., Ltd., vice president of Jiangsu Association for Science ，deputy to the 11th and 12th National People's Congress. Mr. Sun has been dedicatedon new drug development and enterprise management since his graduation. Under hislead, Hengrui Medicine has become a well-known R&D center of antineoplatics andsurgical drugs in China, and one of the most innovative pharmaceutical enterprise.With the aim to be a innovative multinational pharmaceutical group, Hengrui Medicine has set R&D centers in New Jersey,Shanghai, Chengdu, and Lianyungang. Thereare two innovative drugs- Imrecoxib and Apatinib which have been launched, andmany targets under clinical study. The company specializes in the research anddevelopment of antineoplastics, antidiabetics, biologics and drugs for immune system,in which, many of them are under clinical study in US. Injectables and oral dosagehave got authentication from US FDA and EU authority, to become the first Chinesepharmaceutical company to market injectables in US and EU.